STUDY QUESTION: Does fertility preservation using gonadotrophin-releasing hormone (GnRH) analogues during chemotherapy act through a direct effect on the ovary or through inhibition of FSH secretion?
Introduction
Oncological guidelines recommend discussing fertility issues with all young cancer patients treated with gonadotoxic therapies, such as alkylating agents or pelvic irradiation, and to refer them for fertility preservation procedures when required (Munoz et al., 2016) . While cryopreservation of oocytes, embryos, and ovarian tissues remain the most commonly proposed procedures for preservation of fertility of young women and girls, pharmacological ovarian protection has emerged as a very attractive alternative (Roness et al., 2016) . This non-invasive approach can reduce chemotherapy-induced damage and increase the spontaneous ovarian function recovery rate after oncological treatment.
The efficiency of GnRH analogues (GnRHa) for protecting the ovary against damage from chemotherapy was first suggested in animals more than 30 years ago (Chapman and Sutcliffe, 1981; Glode et al., 1981) . Since then, several studies have reported a reduction of ovarian sensitivity to cytotoxic agents when GnRHa were administered during treatment in mice (Meirow et al., 2004; Tan et al., 2010) , rats (Ataya et al., 1985; Bokser et al., 1990; Lemos et al., 2010; Matsuo et al., 2007; Zhao et al., 2010) and monkeys (Ataya et al., 1995) . However, these results were controversial and not confirmed by others (Montz et al., 1991; Danforth et al., 2005; Detti et al., 2014; Horicks et al., 2015; Li et al., 2015) . In humans, recent randomized prospective trials have shown a benefit of GnRHa when administered during chemotherapy to preserve ovarian function in breast cancer patients (Lambertini et al., 2015; Moore et al., 2015) but not in lymphoma patients (Behringer et al., 2010; Demeestere et al., 2016) . Furthermore, mechanisms of GnRHa gonadoprotection have been the subject of debate. GnRHa downregulate the hypothalamic-pituitary-ovarian axis, leading to a profound decrease in gonadotropins levels and to inhibition of folliculogenesis. Follicles that are maintained in the resting stage are potentially more resistant to chemotherapy, suggesting that GnRHa may have an indirect ovarian-protective effect through gonadotropins suppression. However, this theory has been heavily criticized because FSH receptors were not detected in primordial follicles and follicular activation is gonadotropin-independent . Other possible GnRHa actions include a decrease in uteroovarian perfusion or up-regulation of anti-apoptotic molecules through ovarian receptors. GnRH receptors (GnRHR) are mainly expressed in gonadotropic cells in the anterior pituitary but have also been found in peripheral tissues, including the ovary in both humans and rodents (Maggi et al., 2016) . However, ovarian protection through direct effects has not been demonstrated and the role of GnRHR in extrapituitary tissues remains to be elucidated. Thus, there is a real need to further investigate potential mechanisms of action of GnRHa in protecting against chemotherapy-induced ovary damage through direct or indirect mechanisms.
We previously showed that GnRHa did not significantly decrease circulating FSH levels nor inhibit ovarian follicle growth beyond the gonadotropin-dependent stage in mice (Horicks et al., 2015) . These results suggested that GnRHa administration in mice did not inhibit the pituitary-gonadal axis as effectively as in humans despite disruption observed in the oestrus cycles. Therefore, we developed new original models to assess the direct or indirect role of GnRHa in ovarian protection during chemotherapy.
In order to evaluate the potential indirect protective effect of GnRHa through the suppression of pituitary gonadal axis, Fshb-deficient ( −/− ) mice were used to phenocopy the profound inhibition of FSH observed during GnRHa treatment in humans. Potential direct protective effects of GnRHa against chemotherapy-induced damages through their receptors in the ovaries were also evaluated in vitro using two different follicular culture systems; either isolated preantral follicles from prepubertal mice or resting follicles from whole newborn ovaries.
Materials and Methods
The experimental design is illustrated in Fig. 1 .
Ethical approval
All experiments were approved by the Animal Ethics Committee of the Medicine Faculty at the Université Libre de Bruxelles. Animals were maintained under standard conditions of light (12 h light/dark cycle). They had access to food and water ad libitum and all efforts were made to minimize the suffering of the animals following institutional guidelines. A delay of 5 days of accommodation to experimental conditions was mandatory before starting all experiments. (Fig. 1) . The dose of Cy was chosen as it induced a significant follicular loss of around 50% according to our previous results (Horicks et al., 2015) .
Mouse treatments

Preantral follicle culture
Isolated follicles from prepubertal mice (13-14 days old, F1 C57BL/6j × CBA/Ca) were cultured as previously described (Demeestere et al., 2004) . Briefly, preantral follicles (100-120 μm) were mechanically dissected from the ovary and rinsed in Leibowitz L15 medium (Life Technologies, Belgium) supplemented with 10% foetal bovine serum (Life Technologies, Belgium), penicillin (966 IU/ml, Sigma-Aldrich, Belgium) and streptomycin (100 μg/ml, Sigma-Aldrich, Belgium). Follicles were cultured in MEM Alpha Medium-GlutaMAX (Life Technologies, Belgium), with 5%
foetal bovine serum (Life Technologies, Belgium), ITS (recombinant human insulin, human transferrin, and sodium selenite) (0.2 μl/ml, Sigma-Aldrich, Belgium), rFSH (100 mIU/ml, Gonal-F ® , Merck, Belgium), luteinizing hormone (LH, 10 mIU/ml, Sigma-Aldrich, Belgium) for 12 days. Every other day, half of the medium was replaced and stored for further steroidogenesis assessment. Morphology was evaluated and follicles were classified as 'intact' (compact structure), 'enlarged' (broken basal membrane and somatic cells attached to the dish), and 'antral' (antral like cavity formation) ( Supplementary Fig S1) . GnRHa were added every other day from Day 2 (1 μM, triptoreline, (IPSEN, Belgium), and cetrorelix (antagonist), (Merck Serono), Belgium). The dose of GnRH agonist was calculated based on previous in vitro experiments in rodents and pharmacological data in human (Janssens et al., 2000) . A single subcutaneous injection of standard dose of 0.1 mg triptoreline and 0.25 mg cetrorelix in healthy female volunteers leads to a plasma peak concentration of approximatively 2 and 5 ng/ml, respectively. Based on the pharmacological data and previous in vitro experiments, we tested three different doses of 1 nM (similar to physiological concentration), 100 nM and 1 μM. No difference in survival and maturation rate were observed (data not shown) and the highest dose was chosen for this study.
Follicles were then exposed to 4HC (20 μM, 4-hydroperoxycyclophosphamide, active metabolite of Cy, kindly donated by Baxter, Belgium) on Day 4 (Desmeules and Devine, 2006) . Preliminary experiments confirmed that follicular survival and oocyte maturation rate were both significantly reduced at this dose, without completely destroying follicles (data not shown).
Oocyte maturation was triggered on Day 12 by epidermal growth factor (EGF) (5 ng/ml, Roche, Belgium) and human chorionic gonadotropin (hCG, 1.5 IU/ml, Pregnyl ® , Organon, Belgium) ( 
cAMP assay
In some experiments, preantral follicle culture was stopped at Day 8 for cyclic adenosine monophosphate (cAMP) assay. Granulosa cells were collected, washed and directly re-suspended in phosphate-buffered saline (PBS) containing cAMP-specific phosphodiesterase inhibitors (1 mM IBMX and 0.01 mM milrinone Sigma-Aldrich, Belgium). Healthy granulosa cells were counted after staining with Trypan blue (1:1). 200 μl HCl 0.1 M was added to each sample for cell lysis and cAMP was measured in the dried supernatant by radioimmunoassay using a home-made antibody after sample acetylation according to Brooker's work (Brooker et al., 1979) .
Hormonal assays
Estradiol was measured in the culture media collected every 2 days starting at Day 4 of culture until Day 12. Hormones were measured using an electrochemiluminescence immunoassay (Estradiol III, Roche Diagnostics, Germany).
Western blotting
Preantral follicles and LβT3 cells cultured as described (Wang et al., 2014) were serum-starved for 3.5 h prior to triptoreline treatment (1 μM for 10 or 15 min). Cells were then harvested in radioimmunoprecipitation assay (RIPA) buffer containing protease inhibitors and frozen until use. For immunoblotting, lysates were separated using 10% polyacrylamide gels and transferred to polyvinylidene difluoride (PVDF) membranes. Following overnight incubation with primary antibodies (phosphorylated ERK3/ ERK1: Santa Cruz sc-94; TACC3: Upstate Biotechnology 07-233; both used at 1:2000) the blots were incubated with secondary antibodies conjugated to horseradish peroxidase (Promega Biotech, 1:5000). Signals were detected using enhanced chemiluminescence (Yang et al., 2010) . 
Perinatal ovary culture
Ovaries from post-natal Day 4 mice (PND4) were isolated and cultured as previously described (Devine et al., 2004) . Briefly, whole ovaries were placed on silicate membranes covered by a thin film of Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F-12, Life Technologies, Belgium) supplemented with bovine serum albumin (1 mg/ml, Sigma-Aldrich, Belgium), albumax I (1 mg/ml, Life Technologies, Belgium), ascorbic acid (50 μg/ml, Sigma-Aldrich, Belgium), transferrin (27.5 μg/ml, Life Technologies, Belgium), penicillin (5 IU/ml, Sigma-Aldrich, Belgium) and streptomycin (5 μg/ml, Sigma-Aldrich, Belgium). GnRHa and 4HC were added 1 h and 24 h after culture onset, respectively. The ovaries were harvested 22 h post-chemotherapy and fixed for histology or processed for RNA extraction (Fig. 1 ).
Histology and follicular count
Ovaries were fixed in paraformaldehyde 4%, and embedded in paraffin. Microtome serial sections of 5 μm were performed on each whole ovary. One slice out of 10 was stained and observed under a light microscope for morphology and follicular staging following Gougeon's classification (Gougeon, 1996) . Every 50 μm, primordial, primary, secondary, early antral and antral follicles with visible nucleoli into the oocyte were counted. No correction factor was applied.
TdT-mediated dUTP-biotin nick end-labelling (TUNEL)
Apoptosis was assessed by TUNEL staining (In Situ Death Cell Detection Kit, Roche, Belgium). Sections of treated mouse ovary were deparaffinised, rehydrated, and made permeable by proteinase K treatment (20 μg/ml in Tris 10 mM pH7.4, Qiagen, Netherlands). After washing, sections were labelled with TUNEL reagents according to manufacturer's instructions (Roche) and counterstained with Hoechst (1 μg/ml). Sections were observed using a Leica DM 2000 fluorescent microscope.
For TUNEL measurements, two sections per ovary were analysed, one in the periphery and one in the centre of the ovary. The proportion of TUNEL-positive area was calculated by measuring the intensity of the apoptotic signal with respect to the Hoechst signal using ImageJ software (https://imagej.nih.gov/).
Immunohistochemistry
Immunostainings were performed as previously described (Horicks et al., 2015) . Fixed ovarian sections were deparaffinised and rehydrated. Antigen retrieval by heat was performed in citrate buffer pH 6.0 and endogenous peroxidases were inhibited by hydrogen peroxide 1% (Merck Millipore, Belgium). Slides were blocked with serum and incubated with primary antibody (mouse anti-KI-67 1:400, BD Bioscience, Belgium or rabbit anti-GDF9 1:800, Abcam, Belgium) overnight at 4°C. Sections were then incubated in secondary biotinylated antibody (1:300, Vector Laboratories, UK), and processed using an ABC kit according to manufacturer's instructions (Vectastain Elite ABC systems, Vector Laboratories, UK). The reaction was developed with diaminobenzidine (DAB Peroxidase Substrate Kit, Vector Laboratories, UK) followed by counterstaining with haematoxylin.
Statistical analysis
All statistical analyses were performed with the SPSS 24 software (IBM, Belgium). Means were compared by a one-way ANOVA test, after a preliminary Levene's test or by Student's t-test. Significance was confirmed when P < 0.05.
Results
FSH deficiency did not prevent Cy-induced follicular depletion
To examine whether profound inhibition of FSH obtained by GnRHa therapy may prevent chemotherapy-induced ovarian damage, we evaluated the effect of cyclophosphamide (Cy) on FSHb-deficient mice (Fshb
). These mice do not produce FSH and represent a reliable model to assess the effect of FSH on follicular depletion during chemotherapy. Females are infertile as follicular development is arrested at the early antral stage. Nonetheless, follicular development is normal until secondary stage and primordial/primary follicles remain predominant in adult (Demeestere et al., 2012) . As a control for our experiments, Fshb −/− mice were treated with pregnant mare serum gonadotropin (PMSG) during the 5 days prior to chemotherapy and compared with PMSG-untreated Fshb −/− mice (saline injection). The responsiveness of Fshb −/− mice to exogenous gonadotropins was confirmed by the presence of antral follicles ( Fig. 2a) and by an increased expression of aromatase mRNA ( Supplementary Fig. S2 ).
The total number of follicles remained similar between PMSGuntreated and PMSG-treated groups (378 ± 36 and 398 ± 30 follicles/ ovary, respectively) with a non-significant increase of growing follicles in response to PMSG (24 ± 4 and 29 ± 6 follicles/ovary, respectively). The absolute number of each follicular stages is presented in Table I . Cy induced a significant follicular loss of 53% and 63% in the PMSGuntreated and in the PMSG-treated groups, respectively (P = 0.001 and P < 0.0001). All follicular stages were affected, but the depletion was mainly observed in the primordial follicular pool. Primordial/primary follicle population loss reached 54% in the PMSG-untreated group and 66% in the PMSG-treated group compared to their respective controls, leading to a non-significant increase of the growing population (Fig. 2b) . TUNEL staining was significantly higher when mice were treated with Cy ( Fig. 2c and d) whether they received exogenous gonadotropins (P = 0.012) or not (P = 0.002). Similarly, no difference was observed (although no quantification was made) between the chemotherapy-treated groups in cell proliferation as assessed by Ki67 staining or follicle number ( Fig. 2b and d) .
In vitro exposure to GnRHa did not preserve resting follicular population against 4HC damage
The second hypothesis supporting GnRHa gonadoprotective action against chemotherapy is a potential direct effect of the drug on the ovary through GnRH receptors. To investigate this effect, we first confirmed the presence of GnRH receptor mRNA in the ovary from mice at different ages, from post-natal Day 4 to adult as well as in isolated preantral follicles (Supplementary Fig. S3a ). Biological in vitro effect of exogenous GnRH agonist was verified on pituitary cells line (alpha T3) expressing high level of GnRHa receptors (Supplementary Fig. S3b ).
To examine the direct effect of GnRHa on primordial and primary follicles during exposure to chemotherapy, whole post-natal Day 4 (PND4) mouse ovaries containing mainly primordial follicles were exposed to GnRH agonist or antagonist on the first day of culture and to 4HC the day after. The results showed that in vitro exposure to GnRHa alone did not affect follicular distribution and density (Fig. 3a) . Exposure to 4HC induced significant loss of more than 65% of the follicles in all groups (Table II) and morphological modification of the ovary (Fig. 3a and b) . Both GDF9 and Ki67 staining appeared decreased in the oocytes and in the granulosa cells, respectively (Fig. 3b) while a significant increase in apoptosis, targeting mainly granulosa cells, was observed using TUNEL staining ( Fig. 3c and d) . No difference was observed between the 4HC-treated groups in follicular distribution, ovarian morphology and apoptosis whether they were previously exposed to GnRHa or not (Fig. 3b-d) .
In vitro exposure to GnRHa did not reduce direct 4HC damage in growing follicles
To evaluate direct effects of GnRHa on growing follicles in vitro, preantral follicles were continuously exposed to 1 μM of GnRH agonist or antagonist and to 20 μM of 4HC on Day 4 of culture. We found that preantral follicular survival and oocyte maturation were not affected by the presence of GnRH agonist or antagonist alone. However, exposure to 4HC significantly decreased survival and maturation rates whether GnRHa were present or not (Table III) (Fig. 4a) . Follicular development was delayed in all groups exposed to 4HC as shown by late antral cavity formation and abnormal follicular structure (Fig. 4b-d) . Estradiol production increased during follicular culture and levels of estradiol after exposure to 4HC appear reduced but the difference between groups was not significant (Fig. 4e) . Since the canonical signalling pathway of activated GnRHR involves adenylate cyclase, cAMP production was assessed in the granulosa cells (GCs) of preantral follicles cultured for 8 days. cAMP did not increase when GnRH agonist was added 15 min before GCs collection whereas forskolin (FSK) induced a surge of cAMP production (Fig. 5a ). Long-term exposure to GnRH agonist and antagonist did not modify cAMP production. Chemotherapy decreased the mean number of GCs per follicle and therefore the total cAMP level, but cAMP production per 10 6 GCs was not significantly different between groups at Day 8 ( Fig. 5b and c) .
Discussion
In this study, we independently evaluated the effect of FSH inhibition and the potential direct action of GnRHa through GnRH receptors in the ovary exposed to chemotherapy using innovative mice models. We previously demonstrated that GnRHa does not suppress follicular growth even beyond the gonadotropin-dependent stage in mice (Horicks et al., 2015) . Therefore, we used an FSH-deficient mouse model to mimic the profound inhibition of the pituitary axis observed in humans during GnRHa treatment. This model is particularly appropriate to mimic GnRHa-induced gonadotropic inhibition observed in humans and evaluate potential indirect protective effect of FSH depletion during chemotherapy. As previously described (Ezoe et al., 2014; Horicks et al., 2015) , administration of 200 mg/kg Cy-induced dramatic follicular depletion. Here, we showed that damages occurred irrespective of the presence of FSH. To our knowledge, this is the first study showing that the absence of FSH did not prevent Cy-induced follicular loss in mice, suggesting that FSH suppression is not involved in GnRHa's effects on ovarian protection. However, this model selectively targets FSH secretion whereas long-term GnRHa treatment inhibited both gonadotropins even though differences in plasma concentrations were observed between LH and FSH (Matikainen et al., 1992) . Nevertheless, it is unlikely that LH inhibition has an important role in protecting the ovarian reserve given the absence of its receptor before late follicular stages.
These results provide strong evidence to refute the theory that GnRHa protect the ovary against chemotherapy by inhibiting FSH secretion and maintaining follicles at the resting stage in mice (Chapman and Sutcliffe, 1981; Blumenfeld, 2007; Glode et al., 1981) . On the other hand, the loss of growing follicles during chemotherapy induced an increase in FSH levels resulting from the decrease in steroid and inhibin levels. The rise in FSH levels may accelerate follicular development and increase follicular sensitivity to chemotherapy (Blumenfeld, 2007) . This phenomenon may be suppressed in the absence of FSH. However, we did not observe any difference in TUNEL staining between the groups suggesting that the presence of FSH has a limited impact on the apoptotic process of growing follicles during chemotherapy. Secondly, a rapid decline in anti-Müllerian hormone (AMH) levels also occurs during chemotherapy treatment, which induces a massive recruitment of primordial follicles called the 'burn out effect' (Roness et al., 2013) . FSH receptor mRNA but not the protein has been found in early stages, suggesting that the presence of FSH has no effect on follicular 'burn out' phenomenon (Oktay et al., 1997) . Moreover, mechanisms of ovotoxicity differ according to the chemotherapeutic agents and direct toxicity was shown in primordial follicles independently of the recruitment process (Plowchalk and Mattison, 1992; Desmeules and Devine, 2006; Oktem and Oktay, 2007; Morgan et al., 2013; Horicks et al., 2015; Roti Roti et al., 2012) .
Other potential mechanisms of GnRHa protection include a possible direct action on the ovary. This may include a decrease in ovarian circulation due to a hypo-oestrogenic state (Kitajima et al., 2006) or an increase in anti-apoptotic molecules such as sphingosine-1-phosphate (Li et al., 2014) . GnRHR mRNA expression has been reported in Results are expressed as mean ± SEM. n = number of ovaries analysed; Ago = GnRH agonist; Ant = GnRH antagonist; 4HC = 4-hydroperoxycyclophosphamide. a P < 0.05, Results are expressed as mean ± SEM. n = number of experiments; Ago = GnRH agonist; Ant = GnRH antagonist; 4HC = 4-hydroperoxycyclophosphamide. extrapituitary tissues such as the heart, testis, uterus, and ovary in humans and in rodents (Leung et al., 2003; Cheung and Wong, 2008; Maggi et al., 2016; Torrealday et al., 2013) . In the human ovary, GnRHRs are localized in granulosa cells from the antral stage and in the corpus luteum (Choi et al., 2006) . In rats, GnRHR is more widely distributed in the ovary, and GnRHR mRNA is expressed in granulosa cells of all follicles except in the primordial stage and in the corpus luteum (Bauer-Dantoin and Jameson, 1995; Whitelaw et al., 1995) . Although GnRHRs have not been identified in primordial follicles, their presence in ovarian epithelium and stroma suggest a potential effect in immature ovaries as well (Choi et al., 2001) . Here, we confirmed the expression of GnRHR mRNA in mice ovary from post-natal Day 4 to Figure 4 Direct effect of GnRH analogues on growing follicles exposed to chemotherapy. Follicular survival, oocyte maturation (a), and antrum formation (b) were evaluated every other day and at the end of the culture. Preantral follicles were cultured with GnRH agonist 1 μM (Ago), antagonist 1 μM (Antago), 4-hydroperoxycyclophosphamide 20 μM (4HC) alone or together (Ago+4HC, Antago+4HC) and compared to control (Ctrl). *P < 0.05 compared to their respective 4HC-untreated group. Follicular morphology was evaluated every other day. (c) Representative pictures of follicles at Day 6 and (d) Day 12 in different culture conditions. Healthy follicles are defined as an oocyte closely surrounded by cumulus cells and proliferating granulosa cells attached to the bottom of the dish. The pseudo-antrum is well defined between granulosa cells. Development of follicles exposed to chemotherapy appears to be delayed, with less granulosa cells and cumulus cells surrounding the oocyte. Oocytes were more frequently expulsed from the follicles and granulosa cells growth was disorganized. (e) Oestrogen production per 48 h in culture media expressed in mean ± SEM (ng/L).
adult and in isolated preantral follicles. However, no difference was observed in follicular survival and apoptosis after chemotherapy whether the preantral follicles or the immature ovaries were exposed to GnRHa or not. Previous experiments showed that GnRH agonist decreased FSH receptors and FSH-induced cAMP production in rat granulosa cells (Clayton et al., 1979 , Uemura et al., 1994 . However, long-term GnRHa treatment before exogenous FSH hyperstimulation in heifers allowed the recruitment of a larger number of follicles, suggesting that gonadotropins responsiveness is not suppressed (D'Occhio et al., 2013) . In our study, we showed that the presence of GnRHa during follicular culture did not impact estradiol secretion, suggesting that there is no effect of GnRHa on FSH responsiveness in our culture conditions. Others authors showed however a direct dual action of GnRH agonists on steroidogenesis in rat granulosa cells, combining inhibitory and stimulatory effects (Janssens et al., 2000) . It has also been shown that GnRHa administration prior to chemotherapy resulted in a reduction of chemotherapy-induced decrease in estradiol level (Huang et al., 2009) . The role of FSH on ovarian gonadotoxicity and its potential interaction with direct effect of GnRHa appears to be particularly complex as it also modulates essential anti-apoptotic factors affected by chemotherapy (Tsai-Turton et al., 2007; Huang et al., 2009 , Rossi et al., 2017 . For example, glutathione which is depleted by Cy (Devine et al., 2012) while gonadotropins increase the level of protein in the ovaries (Luderer et al., 2001) .
Here, we showed that co-administration of GnRHa did not prevent follicular damage, calling into question the potential direct benefit of GnRHa in both growing and primordial follicles. Oocyte damage in primordial follicles has been already described whereas chemotherapeutic agents targeted granulosa cells in large primary follicles in PND4 mouse ovaries (Desmeules and Devine, 2006) . Direct toxic effects on the oocytes from primordial follicles have also been described in human abortus exposed in vitro to chemotherapy, with 93% of follicular depletion after 48 h and in adult human cortex (Bildik et al., 2015) .
Previous authors have also showed that co-treatment with GnRH agonist did not prevent 4HC and cisplatin damage in vitro using human cortical pieces and granulosa cell lines (Bildik et al., 2015) . The role of GnRH and its analogues on ovarian receptors remains poorly understood and contradictory results have been reported. Moreover, GnRH agonist or antagonist may lead to different pharmacological responses in the ovary. While the desensitization of pituitary receptors during long-term exposure to agonists is well known, the pathways activated by peripheral receptors are less well understood. Inhibitory actions of GnRH agonist on FSH-induced steroidogenesis can be reversed in vitro by concomitant administration of antagonist in rat granulosa cells (Hsueh et al., 1983) . Antagonist might even potentiate the effect of FSH on follicle development in rats (Birnbaumer et al., 1985) . In humans, GnRH can induce apoptosis in granulosa cells through caspase cascade activation, suggesting a role in follicle atresia (Hong et al., 2012) . Direct effects of GnRH agonist on apoptosis and steroidogenesis have also been observed in cultured mammalian granulosa cells at different stages (Takekida et al., 2003) .
In pituitary cells, GnRH binding to its receptor, which is associated with Gαs or Gαq11, activates the phospholipase C -DAG/IP3 pathway or the adenylate cyclase -cAMP pathways, both leading to downstream activation of ERK and p38 mitogen-activated protein (MAP) kinase (Torrealday et al., 2013) . It was previously reported that despite the presence of similar GnRH receptors in granulosa cells and in the pituitary, their intracellular signalling pathway is different (Millar et al., 2008) . Stimulation of mouse granulosa cells with GnRH agonist did not induce activation of cAMP, ERK, or p38 pathways (Torrealday et al., 2013) . We confirmed that cAMP production was not increased after short exposure to GnRH agonist, reflecting the stimulatory flare-up effect prior to downregulation. However, others have shown that GnRH agonist induced a rise in cAMP levels in human cortical pieces and granulosa cell lines, suggesting that the GnRH/GnRHR system may act differently in mice and humans (Bildik et al., 2015) . We previously showed that murine model behaves differently from human generating significant differences in ovarian response to GnRHa. This is the reason why we investigated chemotherapy in a FSH-deficient mouse model, to mimic the human response to GnRHa. However, ovarian GnRHR expression seems to differ between mouse and human. While the rodent receptor contains 327 amino acid, the human receptor has 328 amino acids. The presence of an extra lysine at position 191 appears to be responsible for a lower expression of the human receptor as well as for a faster internalization (Sealfon et al., 1997; Arora et al., 1999) . The functionality of these receptors should be then further investigated in both species. Altogether, our results bring into question whether GnRHa effectively protect ovarian reserve from chemotherapy, both by direct and indirect pathways. It is therefore essential to further investigate the role of GnRH receptors and their signalling pathways in the ovary in mice as well as the mechanisms of action of GnRHa during chemotherapy. Whereas oncological guidelines suggest the use of GnRHa to protect ovarian function during chemotherapy in breast cancer patients, experimental evidence of their efficacy must still be demonstrated.
Supplementary data
Supplementary data are available at Molecular Human Reproduction Online.
